Your browser doesn't support javascript.
loading
ASSESSMENT OF PERFORMANCE AND IMPLEMENTATION CHARACTERISTICS OF RAPID POINT OF CARE SARS-CoV-2 ANTIGEN TESTING IN KENYA
Eva Muthamia; Samuel Mbugua; Mary Mungai; Gama Bandawe; Firdausi Qadri; Zannat Kawser; Shahin Lockman; Louise Ivers; David R. Walt; Sara Suliman; Matilu Mwau; Jesse Gitaka.
Afiliação
  • Eva Muthamia; Mount Kenya University
  • Samuel Mbugua; Mount Kenya University
  • Mary Mungai; Center for Virus Research, Kenya Medical Research Institute
  • Gama Bandawe; Malawi University of Science and Technology
  • Firdausi Qadri; International Center for Diarrheal Disease Research, Bangladesh (icddr,b)
  • Zannat Kawser; Institute for developing Science and Health initiatives (ideSHi)
  • Shahin Lockman; Harvard T.H. Chan School of Public Health
  • Louise Ivers; Massachusetts General Hospital
  • David R. Walt; Brigham and Women's Hospital/Harvard Medical School
  • Sara Suliman; Brigham and Women's Hospital, Harvard Medical School
  • Matilu Mwau; Kenya Medical Research Institute
  • Jesse Gitaka; Mount Kenya University
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21258290
ABSTRACT
BackgroundThe COVID-19 pandemic has resulted in a need for rapid identification of infectious cases. Testing barriers have prohibited adequate screening for SARS COV2, resulting in significant delays in treatment provision and commencement of outbreak control measures. This study aimed to generate evidence on the performance and implementation characteristics of the BD Veritor rapid antigen test as compared to the gold standard test for diagnosis of SARS COV2 in Kenya. MethodsThis was a field test performance evaluation in symptomatic and asymptomatic adults undergoing testing for SARS COV2. Recruited participants were classified as SARS-CoV2-positive based on the locally implemented gold standard reverse transcription polymerase chain reaction (RT-PCR) test performed on nasopharyngeal swabs. 272 antigen tests were performed with simultaneous gold standard testing, allowing us to estimate sensitivity, specificity, positive and negative predictive values for the BD Veritor rapid antigen test platform. Implementation characteristics were assessed using the Consolidated Framework for Implementation Research for feasibility, acceptability, turn-around time, and ease-of-use metrics. Results and DiscussionWe enrolled 97 PCR negative symptomatic and 128 PCR negative asymptomatic, and 28 PCR positive symptomatic and 19 PCR positive asymptomatic participants. Compared to the gold standard, the sensitivity of the BD Veritor antigen test was 94% (95% confidence interval [CI] 86.6 to 100.0) while the specificity was 98% (95% confidence interval [CI] 96 to 100). The sensitivity of BD Veritor antigen test was higher among symptomatic (100%) compared to asymptomatic (84%) participants, although this difference was not statistically significant. There was also a lack of association between cycle threshold value and sensitivity of BD Veritor test. The BD Veritor test had quick turnaround time and minimal resource requirements, and laboratory personnel conducting testing felt that it was easier to use than the gold standard RT-PCR. ConclusionThe BD Veritor rapid antigen test exhibited excellent sensitivity and specificity when used to detect SARS-CoV-2 infection among both symptomatic and asymptomatic individuals in varied population settings in Kenya. It was feasible to implement and easy to use, with rapid turnaround time.
Licença
cc_by_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo diagnóstico / Experimental_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo diagnóstico / Experimental_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...